- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05352191
Beclomethasone in Healthy Athletes
Beclomethasone in Healthy Athletes, Detection in Blood and Urine, and the Effect on Aerobic Performance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a double-blinded, randomized, controlled parallel trial with participants visiting the laboratory on four separate occasions. The purpose of the first visit is to familiarize the participant with the exercise performance protocol as well as to assess a steady state oxygen consumption (VO2) at several submaximal work rates followed by a maximal VO2 (VO2max) test. For a given participant, trials on day two, three, and four will be identical conducted on the same time of day and separated by approximately one week. Beclomethasone or placebo will be delivered daily for one week from test three to test four. Urine and blood samples will be collected after testing on experimental test two and three and self-collected daily during the seven consecutive days of self-administration, and 3, 7 and 14 days after the participants stops taking medication.
Inhaled beclomethasone is approved by the World Anti-Doping Agency (WADA) for use by athletes in and out of competition. The dose used in our study is the highest single dose recommended by the Norwegian medical agency and half of the maximal daily dose recommended. Participants will inhale 800 μg beclometason or placebo using a standard inhaler (Easyhaler) used for asthma treatment. The inhaler delivers 200 μg of beclometasone with each actuation (i.e., 4 puffs/actuations gives 800 μg) with inhalation time being approximately ~1 min (12 breaths) and the manufacturer's user instructions will be followed.
The primary objective is endurance performance measured using a 20 km simulated time trial on a stationary bike. Performance will be measured time to task completion/mean power (watts) and b). Secondary objectives are the physiological response to exercise including: a) heart rate (bpm), b) minute ventilation (Lˑmin-1), c) oxygen uptake (Lˑmin-1), d) oxygen saturation (%), e) respiratory exchange ratio (RER), f) blood lactate and glucose concentration (mmolˑL-1), and f) lung function by spirometry (forced expiratory volume in 1 second, FEV1).
The first 30 participants eligible to the study will be recruited. They must be well trained cyclists and triathletes (VO2max in mLˑkg-1ˑmin-1 ≥60♂/≥50♀) aged between 18 and 35 years. Exclusion criteria include a doctor diagnosed asthma and/or the use of anti-asthmatic medications or glucocorticoids the last 12 months prior to participation. The participants must be free from chest infection for at least 4 weeks prior to assessment; and are not to be taking any medication and have no other health or medical contradictions to them taking part in the study as confirm by information provided on a physical activity readiness questionnaire.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Amund Riiser, PhD
- Phone Number: 92688239
- Email: amund.riiser@hvl.no
Study Contact Backup
- Name: Trine Stensrud, PhD
- Email: trine.stensrud@nih.no
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Healthy Maximal oxygen uptake >60 in male and >50 in female Signed informed consent.
-
Exclusion Criteria:
Intention to compete within 3 days after last dose of medicament Asthma diagnosis Use of anti-asthmatic medication last 12 months Upper chest infection last 4 weeks Contraindication to maximal exercise Contraindication to glucocorticoids Pregnancy or possible pregnancy Failure to obtain written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Beclomethasone
800 ug inhaled once aday for 8 days
|
inhaled 800ug
|
Placebo Comparator: Placebo
one pill once aday for 8 days
|
inhaled 800ug
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
20km cycling timetrial performance
Time Frame: 3 weeks
|
ergometer
|
3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection of beclometasone in urine and dried blood spots
Time Frame: 3 weeks
|
blood and urine samples
|
3 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Amund Riiser, PhD, Western Norway University of Applied Sciences
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 123 (Giresun University Scientific Research Project)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Performance, Detection
-
Shanghai 6th People's HospitalNot yet recruitingTo Evaluate the Spinal Instability Detection Performance of the DLS
-
Taipei Veterans General Hospital, TaiwanRecruiting
-
Harvard Pilgrim Health CareDuke University; Brigham and Women's Hospital; University of California, San... and other collaboratorsActive, not recruiting
-
Quanovate Tech Inc.Recruiting
-
Thrive Earlier Detection CorpCompletedEarly Cancer DetectionUnited States
-
CareTaker Medical LLCCompletedRespiration Rate Detection
-
Women's College HospitalOttawa Hospital Research Institute; Cancer Care Ontario; Laval University; Ontario...CompletedClinical Trial | Early Detection of CancerCanada
-
Attikon HospitalCompletedSonographic Detection of Musculocutaneous NerveGreece
-
ClinLogic LLCMDGlobalRecruitingEarly Detection of CancerUnited States
Clinical Trials on Beclomethasone
-
West Penn Allegheny Health SystemCompleted
-
Adamis Pharmaceuticals CorporationWithdrawn
-
Adamis Pharmaceuticals CorporationWithdrawn
-
SOFAR S.p.A.Completed
-
Lawson Health Research InstituteCompleted
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Research in Real-Life LtdTeva Branded Pharmaceutical Products R&D, Inc.CompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
Research in Real-Life LtdTeva Branded Pharmaceutical Products R&D, Inc.Completed
-
SoligenixNational Cancer Institute (NCI)Completed